1. Home
  2. MESO vs TIXT Comparison

MESO vs TIXT Comparison

Compare MESO & TIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • TIXT
  • Stock Information
  • Founded
  • MESO 2004
  • TIXT 2005
  • Country
  • MESO Australia
  • TIXT Canada
  • Employees
  • MESO N/A
  • TIXT N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • TIXT EDP Services
  • Sector
  • MESO Health Care
  • TIXT Technology
  • Exchange
  • MESO Nasdaq
  • TIXT Nasdaq
  • Market Cap
  • MESO 1.1B
  • TIXT 1.1B
  • IPO Year
  • MESO N/A
  • TIXT 2021
  • Fundamental
  • Price
  • MESO $10.18
  • TIXT $3.58
  • Analyst Decision
  • MESO Strong Buy
  • TIXT Hold
  • Analyst Count
  • MESO 4
  • TIXT 9
  • Target Price
  • MESO $11.50
  • TIXT $5.78
  • AVG Volume (30 Days)
  • MESO 215.6K
  • TIXT 400.2K
  • Earning Date
  • MESO 08-28-2024
  • TIXT 11-08-2024
  • Dividend Yield
  • MESO N/A
  • TIXT N/A
  • EPS Growth
  • MESO N/A
  • TIXT N/A
  • EPS
  • MESO N/A
  • TIXT N/A
  • Revenue
  • MESO $5,902,000.00
  • TIXT $2,659,000,000.00
  • Revenue This Year
  • MESO $66.05
  • TIXT N/A
  • Revenue Next Year
  • MESO $348.27
  • TIXT $2.80
  • P/E Ratio
  • MESO N/A
  • TIXT N/A
  • Revenue Growth
  • MESO N/A
  • TIXT 0.49
  • 52 Week Low
  • MESO $1.61
  • TIXT $2.83
  • 52 Week High
  • MESO $12.18
  • TIXT $11.51
  • Technical
  • Relative Strength Index (RSI)
  • MESO 54.91
  • TIXT 44.83
  • Support Level
  • MESO $10.00
  • TIXT $3.39
  • Resistance Level
  • MESO $10.98
  • TIXT $4.60
  • Average True Range (ATR)
  • MESO 0.59
  • TIXT 0.29
  • MACD
  • MESO 0.06
  • TIXT -0.05
  • Stochastic Oscillator
  • MESO 47.92
  • TIXT 15.70

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares

TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.

Share on Social Networks: